Abaloparatide
A synthetic version of the first 34 amino acids of PTHrP, injected daily to build bone in osteoporosis
Abaloparatide is a synthetic analog of the first 34 amino acids of parathyroid hormone-related peptide, injected once a day. Approved as Tymlos in 2017 for osteoporosis at high fracture risk, it reduced new spine fractures against placebo in the ACTIVE trial.
Manufacturer's recommended dosing (FDA label): 80 µg, Once daily, at about the same time, Subcutaneous, periumbilical abdomen Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
Work out syringe units → · New to syringes? · All dosing data ↓
What is it?
Parathyroid hormone and its relative, parathyroid hormone-related peptide (PTHrP), act on the same receptor, PTH1R. Teriparatide was the first drug to use a brief daily pulse there to build bone. Abaloparatide is the second: an analog of the first 34 amino acids of PTHrP, described in its phase 3 report as a selective activator of the type 1 PTH receptor.
In the ACTIVE trial, 2,463 postmenopausal women took abaloparatide, placebo or teriparatide for 18 months. Spine and non-spine fractures were less frequent on abaloparatide than on placebo, and high blood calcium was less common than on teriparatide, 3.4% against 6.4%. After two further years on alendronate, 0.9% of women who had started on abaloparatide had a new spine fracture, against 5.6% who had started on placebo.
The benefit held among the women most at risk. In the 2,026 ACTIVE participants who met guideline definitions of high fracture risk, new spine fractures occurred in 0.72% on abaloparatide against 4.77% on placebo. In men, the ATOM trial measured bone density rather than fractures: spine density rose 8.48% against 1.17% on placebo over a year, and that is why the men's indication is to increase bone density. A Japanese dose-finding study showed the effect scales with dose, 80 µg outperforming 40 µg.
Claims data compare it with teriparatide in practice. Among more than 11,000 matched patients on each, non-vertebral fractures and cardiovascular events were similar. Osteosarcoma is the standing concern, because abaloparatide caused it in rats at 4 to 28 times the human exposure (label); in 44,728 patients prescribed teriparatide or abaloparatide, primary bone cancer was no more common than in matched controls. Not every hoped-for use worked: in a small trial after pelvic fracture, abaloparatide did not speed healing.
Tymlos is approved in the US for postmenopausal women and men with osteoporosis at high fracture risk. The dose is 80 µg once a day under the skin of the abdomen, and use beyond two years in a lifetime is not recommended. First doses are taken sitting or lying down, as blood pressure can drop on standing; the label also warns about allergic reactions, osteosarcoma risk and high blood calcium.
Mechanism of Action
Abaloparatide is an analog of PTHrP(1-34) that activates the PTH1 receptor; given once a day as a brief pulse, it stimulates bone-forming cells (label).
PTH1 receptor
Acts as an agonist at PTH1R and switches on cAMP signalling in target cells (label).
Bone formation
Once-daily dosing stimulates osteoblasts on trabecular and cortical bone; the formation marker PINP rose 140.7% on 80 µg in the Japanese study.
A short pulse
Levels peak about 30 minutes after injection and the half-life is about 1 hour, so exposure is brief each day (label).
Published Research
The studies behind abaloparatide, read from their PubMed abstracts.
ACTIVE: abaloparatide against placebo, 2,463 women
Postmenopausal women received abaloparatide 80 µg daily, placebo or teriparatide for 18 months. Spine and non-spine fractures were less frequent than on placebo and bone density rose more (P < .001); high blood calcium occurred in 3.4% against 6.4% on teriparatide.
ACTIVExtend: alendronate after abaloparatide, 1,139 women
Women who finished ACTIVE took alendronate for up to 24 months. Over 43 months, 0.9% who had started on abaloparatide had a new spine fracture against 5.6% who had started on placebo, an 84% relative risk reduction.
ATOM: men with osteoporosis, 228 randomized
Men aged 40 to 85 took abaloparatide 80 µg or placebo daily for 12 months. Spine bone density rose 8.48% against 1.17%, total hip 2.14% against 0.01% (both p < 0.0001); injection-site reactions, dizziness and headache were among the commonest side effects.
ACTIVE-J: Japanese women and men, 78 weeks
Abaloparatide 80 µg daily for 78 weeks raised spine bone density 12.5% more than placebo, and total hip and femoral neck density 4.3% more each.
A skin patch against the injection, 511 women
Women used an experimental abaloparatide skin patch or the injection daily for 12 months. Spine bone density rose 7.14% with the patch against 10.86% with the injection, missing the trial's 2.0-point non-inferiority margin; application-site reactions affected 94.4% against 70.5%.
Insurance claims: abaloparatide against teriparatide
Among propensity-matched women aged 50 and over, hip fractures over 18 months occurred in 1.1% on abaloparatide against 1.4% on teriparatide (hazard ratio 0.83), and non-spine fractures in 4.4% against 5.0%. Observational, not randomized.
Women at the highest fracture risk
In the 2,026 ACTIVE participants who met guideline criteria for high fracture risk, new spine fractures occurred in 0.72% on abaloparatide, 0.99% on teriparatide and 4.77% on placebo; major osteoporotic fractures in 1.6%, 3.0% and 6.8%.
Japanese dose-finding, 48 weeks
In postmenopausal Japanese women at high fracture risk, spine bone density rose 6.6% on 40 µg and 11.5% on 80 µg more than placebo; adverse events were more common on abaloparatide but mild to moderate.
Claims data: heart safety against teriparatide
Among 11,616 propensity-matched patients per group, non-vertebral fractures over 19 months were similar to teriparatide (hazard ratio 0.89) and major cardiovascular events occurred at similar rates.
Bone cancer in 44,728 patients
In 44,728 patients over 50 prescribed teriparatide or abaloparatide, primary bone cancer occurred in 0.02% against 0.05% of matched controls who had no known risk factors (risk ratio 0.47).
Pelvic fracture healing: no benefit
In 48 adults aged 50 and older randomized within four weeks of a pelvic fracture, CT healing at three months was no better than placebo (39% against 64% of patients healed, not significant), and pain and mobility did not differ.
Dosing Data
Tymlos is 80 µg injected under the skin of the abdomen once a day, with calcium and vitamin D if the diet falls short.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Tymlos (abaloparatide injection): Injection: 3120 mcg/1.56 ml (2000 mcg/ml) of abaloparatide in clear, colorless solution in a single-patient-use prefilled pen. The prefilled pen delivers 30 daily doses of 80 mcg abaloparatide in 40 mcl. Forms the label lists: single-patient-use prefilled pens.
Source: Tymlos (abaloparatide injection) label, section 3 (DailyMed version 19, effective August 11, 2026).
Mixing a vial: a worked example
Nothing to mix: the label gives Tymlos (abaloparatide injection) as single-patient-use prefilled pens, ready to use.
Source: Tymlos (abaloparatide injection) label, sections 2, 3 and 16 (DailyMed version 19, effective August 11, 2026).
Storage before and after mixing
Before mixing or first use: “Storage and Handling Before first use, store TYMLOS under refrigeration between 2°C to 8°C (36°F to 46°F).” “Do not freeze or subject to heat.”
After mixing or first use: “After first use, store for up to 30 days at 20°C to 25°C (68°F to 77°F).”
Source: Tymlos (abaloparatide injection) label, sections 16 and 2 (DailyMed version 19, effective August 11, 2026).
How it is taken
As the approved label gives it: Subcutaneous, periumbilical abdomen (Once daily, at about the same time; Label: osteoporosis at high fracture risk (postmenopausal women; men, to increase bone density)).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of about 1 hour after subcutaneous injection. After about five half-lives almost none is left.
How long the doses were given: Label: osteoporosis at high fracture risk (postmenopausal women; men, to increase bone density): Up to 2 years in a lifetime.
When effects appear: unknown; no source on this page gives a time to effect for Abaloparatide. Results reported in the studies are under Published Research.
Source: half-life: Tymlos prescribing information, section 12.3 (DailyMed set 712143d9-e21e-4013-bb3b-3426a21060a8, effective August 11, 2026; read October 2, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Injection-site reactions, dizziness and headache were among the most common in men (ATOM); High blood calcium: 3.4% against 6.4% on teriparatide (ACTIVE); Application-site reactions in most users of the experimental patch. Full list and cautions ↓
When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Abaloparatide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the trials above”).
Interactions
Unknown: a PubMed search for human interaction studies of Abaloparatide (reviewed 2026-10-06) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Abaloparatide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Abaloparatide's expected mass, 3,961.0 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (Approved in the US as Tymlos (abaloparatide injection), NDA 208743, first approved April 28, 2017). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the trials above.
Contraindications & Cautions
From the Tymlos label (DailyMed, effective August 11, 2026).
Legal Status
Abaloparatide is approved in the US as Tymlos.
Frequently Asked Questions
?What is abaloparatide?
A synthetic analog of the first 34 amino acids of parathyroid hormone-related peptide, injected once a day to build bone. It is sold in the US as Tymlos.
?How is it different from teriparatide?
Both give a daily pulse at the same receptor; teriparatide copies parathyroid hormone, abaloparatide PTHrP. High blood calcium was less common on abaloparatide in ACTIVE, 3.4% against 6.4%.
?What dose is used?
The labelled dose is 80 micrograms under the skin of the abdomen once a day.
?Does it prevent fractures?
In ACTIVE, spine and non-spine fractures were less frequent than on placebo over 18 months; with two years of alendronate afterwards, new spine fractures occurred in 0.9% against 5.6%.
References
- [fda] FDA. Drugs@FDA (openFDA): TYMLOS (abaloparatide) injection, NDA 208743, original approval April 28, 2017, prescription. Read October 2, 2026.
- [fda] FDA. Tymlos (abaloparatide) injection US prescribing information (DailyMed set 712143d9-e21e-4013-bb3b-3426a21060a8, version 19, effective August 11, 2026). Read October 2, 2026.
- [clinical-trial] Miller PD, et al. "Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial." JAMA, 2016;316(7):722-33. PMID: 27533157.
- [clinical-trial] Bone HG, et al. "ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis." J Clin Endocrinol Metab, 2018;103(8):2949-2957. PMID: 29800372.
- [clinical-trial] Czerwinski E, et al. "The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial." J Bone Miner Res, 2022;37(12):2435-2442. PMID: 36190391.
- [clinical-trial] Matsumoto T, et al. "Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study." J Clin Endocrinol Metab, 2022;107(10):e4222-e4231. PMID: 35977548.
- [clinical-trial] Lewiecki EM, et al. "Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study." J Bone Miner Res, 2023;38(10):1404-1414. PMID: 37417725.
- [pubmed] Tabatabai L, et al. "Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis." Endocr Pract, 2025;31(2):159-168. PMID: 39551187.
- [pubmed] DeSapri KT, et al. "Effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with osteoporosis at highest risk for fracture." Menopause, 2025;32(5):388-395. PMID: 39999474.
- [pubmed] Matsumoto T, et al. "Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study." J Bone Miner Metab, 2023;41(6):807-816. PMID: 37505256.
- [pubmed] Cosman F, et al. "Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study." Osteoporos Int, 2022;33(8):1703-1714. PMID: 35524068.
- [pubmed] McDonald CL, et al. "Treatment of Osteoporosis With Anabolic Agents and the Risk of Primary Bone Cancers: A Study of 44,728 Patients Treated With Teriparatide and Abaloparatide." J Am Acad Orthop Surg, 2023;31(10):520-528. PMID: 36913523.
- [pubmed] Nieves JW, et al. "Abaloparatide and pelvic fracture healing: a phase 2 randomized placebo-controlled trial." Osteoporos Int, 2026. PMID: 42618812.
Sources & Citations
Studies were read from their PubMed abstracts; the Tymlos label (DailyMed version 19, effective August 11, 2026) was read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.